Poster-Disease-modifying Therapy
October 25, 2021
Pregnancy Outcomes in the Ozanimod Clinical Development Program in Relapsing Multiple Sclerosis, Ulcerative Colitis, and Crohns Disease
Background: Ozanimod, an oral sphingosine 1-phosphate (S1P) receptor modulator selectively targeting S1P1 and S1P5, is approved in the US...
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Concurrent Administration of Ozanimod and Serotonergic Antidepressants in Patients with Relapsing Multiple Sclerosis
Background: Ozanimod is approved in the US for the treatment of adults with relapsing multiple sclerosis (RMS) and in the EU and Canada for...
Poster-Disease-modifying Therapy
October 25, 2021
Clinical Outcomes in Patients with COVID-19 Infection during Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis
Background: The COVID-19 pandemic has become a significant concern for patients with multiple sclerosis (MS) and their healthcare...
Poster-Disease-modifying Therapy
October 25, 2021
Online Medical Education Increases Knowledge Among Neurologists of Safety Considerations for Disease Modifying Therapies in Multiple Sclerosis
Background: Disease modifying therapies (DMTs) have transformed the management of multiple sclerosis (MS). Patients can now live many years...
Poster-Disease-modifying Therapy
October 25, 2021
Classic-MS: Long-Term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis Who Received Cladribine Tablets in Phase III Parent Trials
Background: CLASSIC-MS (NCT03961204) explores the long-term efficacy and durability of effect of cladribine tablets (CladT; cumulative dose...
Poster-Disease-modifying Therapy
October 25, 2021
Safety and Effectiveness of Peginterferon Beta-1a in a Subgroup of African American Patients: Plegridy Observational Program Interim Analysis
Background: Limited data on baseline (BL) characteristics and disease severity exist for Black/African American (AA) patients with multiple...
Poster-Disease-modifying Therapy
October 25, 2021
Comparable Ofatumumab Treatment Outcomes in Patients across Racial/Ethnic Groups in the Asclepios I/II and Apolitos Studies
Background: Ofatumumab is a fully human anti-CD20 monoclonal antibody approved by the FDA for treatment of adults with relapsing multiple...
Poster-Disease-modifying Therapy
October 25, 2021
Does Frequency and Severity of COVID-19 Differ By Disease Modifying Therapy in MS Patients?
Background: Some authors have reported positive associations between B-cell-depleting (anti-CD20) therapies and COVID-19 infection risk or...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder
Background: In the randomized, double-blind, placebo-controlled, phase 3 PREVENT trial (NCT01892345), eculizumab was well tolerated and...
Poster-Disease-modifying Therapy
October 25, 2021
Acapella: B-Cell Repletion in Ocrelizumab-Treated Patients
Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for treatment of relapsing remitting (RRMS) and primary...